ARV-766 is also designed to target T878X, H875Y and less frequent mutations. All three of the patients with co-occurring H875, T878 and L702H mutations had a 50% or greater reduction in PSA levels.

Meanwhile, in the prostate cancer trial, ARV-110 reduced prostate-specific antigen (PSA) levels by at least 50% in two of five patients with specific mutations of the androgen receptor (AR ...